LRMR Stock Discussion
Larimar Therapeutics, Inc. Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
Industry: Biotechnology
Keywords: Medicine Biotechnology Drug Discovery Rare Diseases Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders
Recent Comments
- Cos3 on Adding float as advanced filter criteria?
- FriendlyOyster657 on BOOT
- TraderMike on Filtering by News?
- Dr_Duru on Filtering by News?
- TraderMike on Filtering by News?
From the Blog
Featured Articles